MORGAN STANLEY PLC/CALL/ABBVIE/260/0.1/17.01.25 | Market Closed - Bid/Ask 02:32:44 2024-07-17 pm EDT | After market 03:11:34 pm | |||
| 0.071 EUR | +12.70% |
|
0.077 | +8.45% |
| 1 month | +3.28% | ||
| 3 months | -1.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ABBVIE INC.
Latest news about ABBVIE INC.
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.071 | +12.70% |
| 24-07-16 | 0.063 | -1.56% |
| 24-07-15 | 0.064 | +1.59% |
| 24-07-12 | 0.063 | 0.00% |
| 24-07-11 | 0.063 | +1.61% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 02:32 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ABBVIE INC. |
| Issuer | Morgan Stanley |
| WKN | MB0YNS |
| ISIN | DE000MB0YNS7 |
| Date issued | 2022-11-24 |
| Strike | 260 $ |
| Maturity | 2025-01-17 (184 Days) |
| Parity | 10 : 1 |
| Emission price | 0.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.52 € |
|---|---|
| Lowest since issue | 0.014 € |
| Spread | 0.009 € |
| Spread % | 11.25% |
Company Profile
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
Consensus: AbbVie Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
169.2
USD
Average target price
183.8
USD
Spread / Average Target
+8.61%
- Stock Market
- Warrants
- Warrant
